TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23088524
Drug: Hyaluronan gels
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan gels applied during the first 2 weeks after SRP (n = 17)
Study: 16770728
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg daily for 6 weeks)
Study: 16770728
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 6 weeks)
Study: 8996149
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with six cycles of 5FU (425 mg/m2) plus leucovorin (20 mg/m2) by rapid intravenous injection daily for 5 consecutive days every 4 to 5 weeks
Study: 21199130
Drug: 0.5 mg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg·kg(‐1) ketorolac IV
Study: 21199130
Drug: 1 mg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg·kg(‐1) ketorolac IV
Study: 16946218
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 400 mug
Study: 16946218
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol 400 mug
Study: 10776826
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg/day orally
Study: 12027844
Drug: Mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.2 mg/kg
Study: 1598824
Drug: Tablet A
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet A (300 mg ofloxacin)
Study: 1598824
Drug: Tablet B
Normalized name: Biaxin 4 Tablet Blister Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B (300 mg ofloxacin)
Study: 27305037
Drug: Hypofractionated whole‐breast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated whole‐breast irradiation (HF‐WBI) at a dose of 42.56 grays in 16 fractions plus a tumor bed boost
Study: 27305037
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated whole‐breast irradiation (CF‐WBI) at a dose of 50 grays in 25 fractions plus a tumor bed boost
Study: 27305037
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (CF‐WBI and HF‐WBI)
Study: 21867844
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg/ezetimibe 10 mg
Study: 16436852
Drug: Levobupivacaine (0.25%)
Normalized name: levobupivacaine 0.25 MG/ML
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine (0.25%) bolus with saline infusion (group I)
Study: 16436852
Drug: Levobupivacaine (0.25%)
Normalized name: levobupivacaine 0.25 MG/ML
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine (0.25%) bolus and infusion (group II)
Study: 16436852
Drug: Saline bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline bolus (30 ml) plus saline infusion (270 ml at 5 ml/h, placebo group)
Study: 15123483
Drug: Enteral rehydration
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral rehydration therapy
Study: 9017769
Drug: Furosemide products
Normalized name: furosemide Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide products (one intravenous and four oral tablet formulations)
Study: 3674221
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (7 mg/kg)
Study: 1101066
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer globulin (3 ml, repeated at four months)
Study: 1101066
Drug: Intermediate titer
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate titer globulin (3 ml, repeated at four months)
Study: 1101066
Drug: Normal titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal titer globulin (3 ml, repeated at four months)
Study: 26036793
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT scan (Group A): Tube voltage 120 kVp, automatic current modulation with a Noise Index of 12, ASIR 30%, injected with Iohexol (350 mgI/ml)
Study: 26036793
Drug: Spectral CT
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectral CT Imaging (Group B): Tube current of 600 mA, injected with Iodixanol (270 mgI/ml)
Study: 23322408
Drug: Chitosan-dextran (CD)
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan-dextran (CD) gel applied unilaterally
Study: 23322408
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no gel applied on contralateral sides)
Study: 21761711
Drug: Clarithromycin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS with nasal polyps
Study: 21761711
Drug: Clarithromycin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS without nasal polyps
Study: 17289155
Drug: Higher levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher levels of nicotine dependence and concurrent hazardous use of alcohol or cannabis
Study: 15229205
Drug: Individualized GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized GnRH antagonist regimen (flexible regimen)
Study: 15229205
Drug: Standard GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GnRH antagonist regimen (fixed regimen)
Study: 9205816
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of rhIL-11 at 10-50 micrograms kg-1 for 1 or 3 hours
Study: 9205816
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of rhIL-11 at 3-50 micrograms kg-1
Study: 9205816
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of rhIL-11 at 3 micrograms kg-1 once daily for 7 days
Study: 9205816
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of rhIL-11 at 50 micrograms kg-1
Study: 9205816
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of rhIL-11
Study: 8381643
Drug: Clotrimazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (200 mg/day)
Study: 2957801
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg once daily for the first 2 days, then 20 mg once daily for 5 days
Study: 18973893
Drug: Daily 100
Normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily 100 mg aspirin
Study: 29475433
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of 24% sucrose
Study: 29475433
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of 24% sucrose
Study: 29475433
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml of 24% sucrose
Study: 29475433
Drug: All sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All sucrose doses
Study: 23707316
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol absorption (measured by cholestanol-to-cholesterol ratio, CR)
Study: 23707316
Drug: Cholesterol absorption
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol absorption (CR)
Study: 20712886
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine monotherapy (1250 mg/m2 twice daily)
Study: 20712886
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and vinorelbine (dose level 2)
Study: 16699663
Drug: Normal Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Tenon's capsule
Study: 15298634
Drug: Lansoprazole orally
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube
Study: 15298634
Drug: Intact lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Study: 3541596
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 or 20 mg orally three times daily)
Study: 20694775
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (CM)
Study: 20694775
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WM)
Study: 18471409
Drug: Astragalous Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalous Injection
Study: 8678496
Drug: Simultaneous combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous combination of TAM & MPA
Study: 8678496
Drug: Alternating sequential
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating sequential combination of TAM plus MPA (TAM‐MPA)
Study: 8678496
Drug: MPA as
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA as second-line therapy after TAM
Study: 1765356
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg uid
Study: 6357037
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Control)
Study: 30524749
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone used in conjunction with iNO
Study: 27491224
Drug: Liuwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuwei Dihuang Pill (LDP) and Ginkgo Leaf Tablet (GLT)
Study: 27491224
Drug: Liuwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuwei Dihuang Pill (placebo) and Ginkgo Leaf Tablet (placebo)
Study: 16361624
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg orally once a day
Study: 16361624
Drug: Gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 500 mg orally once a day
Study: 10798055
Drug: Prednisolone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (daily 60 mg/m2 for 4 weeks, then 45, 30, 20, 10, 5 mg/m2 on alternate days for 4 weeks)
Study: 10798055
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone (HDMP) (30 mg/kg/d for 3 days, 20 mg/kg/d for 4 days, 10 mg/kg/d for 1 week)
Study: 8576660
Drug: I.M. method
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. method (Intramuscular)
Study: 2127674
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nicergoline
Study: 27509187
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 3000 IU/day
Study: 24809921
Drug: Trimetazidine treatment
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine treatment group (TG)
Study: 24809921
Drug: Trimetazidine treatment
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine treatment
Study: 21968279
Drug: Adrenocorticotropic hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenocorticotropic hormone stimulation
Study: 19648224
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Modafinil
Study: 17504903
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg im (first dose), followed by 500 mg im every 6 weeks
Study: 17504903
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) plus oral levonorgestrel (LNG) 250 microg/d
Study: 17504903
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment only
Study: 9653685
Drug: Joint mobilization
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint mobilization and comprehensive treatment (hot packs, active range of motion, physiologic stretching, muscle strengthening, soft tissue mobilization, and patient education)
Study: 9653685
Drug: Joint mobilization
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint mobilization and comprehensive treatment
Study: 9653685
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment alone
Study: 26522708
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks through week 24 and every 8 weeks through week 48.
Study: 26522708
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser at baseline and IAI every 8 weeks after 3 monthly doses from week 24 onward (laser/IAI group).
Study: 26522708
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg.
Study: 24029269
Drug: Nicotinamide 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 500 mg twice/day
Study: 18556747
Drug: Icodextrin-containing PD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin-containing PD solutions (Extraneal)
Study: 18556747
Drug: Non-icodextrin-containing PD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-icodextrin-containing PD solutions
Study: 16979005
Drug: Pharmacologic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic Therapy (PT) alone
Study: 14551366
Drug: Low-dose spironolactone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spironolactone (25 mg three times/week)
Study: 11256554
Drug: Pranlukast (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (450 mg/day)
Study: 11256554
Drug: Bronchodilators and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day)
Study: 11256554
Drug: Bronchodilators alone
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators alone
Study: 8171288
Drug: Activated peroral
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated peroral charcoal (50 g 3 times a day for 8 days)
Study: 3146125
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g single dose at the time of surgery)
Study: 18585635
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy with maintenance protocol
Study: 18585635
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy with maintenance treatment
Study: 18585635
Drug: BCG maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG maintenance treatment
Study: 18585635
Drug: SWOG protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWOG protocol for BCG therapy
Study: 18585635
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of BCG
Study: 18585635
Drug: Individualized approach
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized approach to BCG therapy
Study: 10999784
Drug: Metyrapone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (500 mg every 4 h)
Study: 9081136
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) 60 micrograms, intravenous infusion, 5 days a week for 4 weeks, followed by twice a week for 4 weeks
Study: 29231562
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of western medication
Study: 24405492
Drug: Threshold suspend
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold suspend (TS) feature, insulin stopped for 2 hours once SG value of ≤70 mg/dL detected
Study: 24405492
Drug: Control (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (basal insulin delivery continued)
Study: 19931156
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg as an intermittent bolus 3 times a day)
Study: 19931156
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg as an intermittent bolus twice a day)
Study: 15288222
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the vaginal vault
Study: 15288222
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the cervix
Study: 8689733
Drug: Geristore restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geristore restoration system after cavity cleaned with 10% NaOCl solution and 3% H2O2 solution (Group G)
Study: 8689733
Drug: Geristore restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geristore restoration system after cavity applied with Mirage-Bond (Group MG)
Study: 3803702
Drug: Esaprazole 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaprazole 900 mg
Study: 3583500
Drug: Esaprazole 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaprazole 1800 mg
Study: 30825795
Drug: Nicotine Patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine Patch
Study: 21926186
Drug: subcutaneous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous placebo + methotrexate
Study: 15343195
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin injection therapy
Study: 11177203
Drug: Bicarbonate-rich mineral
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-rich mineral water (1715 mg bicarbonate/l)
Study: 9051880
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 0.5 g daily for 2 years
Study: 8378156
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (50 mg/kg)/promethazine (1 mg/kg)
Study: 8378156
Drug: Meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1 mg/kg)/promethazine (1 mg/kg)
Study: 2878859
Drug: Azodisal sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azodisal sodium (1 g/day)
Study: 2878859
Drug: Azodisal sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azodisal sodium (1 g/day vs 2 g/day)
Study: 2878859
Drug: Azodisal sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azodisal sodium (2 g/day)
Study: 2878859
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or sulphasalazine (2 g/day)
Study: 24377219
Drug: Medication (M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (M group)
Study: 14746859
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg, ondansetron 32 mg i.v., dexamethasone 12 mg on day 1, aprepitant 80 mg and dexamethasone 8 mg on days 2-3, dexamethasone 8 mg on day 4
Study: 14746859
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ondansetron 32 mg i.v. and dexamethasone 20 mg on day 1, dexamethasone 8 mg b.i.d. on days 2-4)
Study: 8510490
Drug: 12-month course
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month course of alfa interferon therapy
Study: 3319536
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day GVG
Study: 3319536
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day GVG
Study: 23432812
Drug: PHiD‐CV co‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV co‐administered with DTPa‐HBV‐IPV/Hib
Study: 17534460
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics as initial therapy for adults without compelling indications for other agents.
Study: 17534460
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, long-acting CCBs, ARBs, or beta-blockers as first-line therapy for diastolic and/or systolic hypertension.
Study: 17534460
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors recommended for nondiabetic chronic kidney disease patients.